Elizabeth L. Seashore, MD

Department or Service


  • Texas Medical Center


Blood Disorders

Phone: 832-822-4242

Contact Information

6701 Fannin St., Ste. 1510
Houston, TX 77030
United States
Texas US

Research Laboratory

Research Area

  • Cancer
  • Leukemia

Instructor, Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine


School Education Degree Year
Baylor College of Medicine fellowship Pediatric Hematology/Oncology 2019
NY-Presbyterian Hospital, Columbia University Medical Center residency Pediatrics 2016
Boston University School of Medicine medical school Doctor of Medicine 2013
Brandeis University bachelors Bachelor of Science, Biology and Philosophy 2006


Dr. Seashore first developed a passion for oncology as a clinical research coordinator in adult blood cancers at the University of California, San Francisco, prior to medical school. Her love of caring for children drew her to pediatric oncology, where she is as excited by the science of cancer as she is inspired by her incredible patients and their families.

As a pediatric hematology and oncology fellow, Dr. Seashore treated a wide variety of blood diseases and cancers. She is specifically interested in pediatric leukemia. Dr. Elizabeth Seashore completed her pediatric hematology/oncology fellowship training in 2019. 

She believes in not only providing the very best cancer treatment for each individual child, but also ensuring excellent quality of life, and plans to pursue additional training in palliative care.  

Board Certifications
American Board of Pediatrics


Organization Name Role
American Academy of Pediatrics (AAP) Member
American Society of Hematology (ASH) Member
American Society of Pediatric Hematology/Oncology (ASPHO) Member
Children's Oncology Group (COG) Member

Research Statement

Dr. Seashore's current research interests include advancing the understanding of pediatric blood cancers, specifically acute myeloid leukemia (AML). She is conducting laboratory research aimed at identifying unique characteristics of leukemia stem cells, which can be resistant to standard chemotherapy and cause relapse. She hopes that her findings can ultimately be used to eliminate these stem cells with targeted therapies.